Healthcare Takes A Big Step Forward With The Help of A.I.

To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.

Click here to learn more about the booming eHealth industry - and see which microcap will be at the

Elizabeth M. Keiley net worth and biography

Elizabeth Keiley Biography and Net Worth

General Counsel of Entasis Therapeutics

Elizabeth Keiley has served as our general counsel since April 2019. Prior to this, Ms. Keiley served in a variety of positions at Oxford Immunotec Global PLC, a publicly traded global diagnostics company, including most recently serving as Senior Vice President and General Counsel. Prior to joining Oxford Immunotec in 2012, Ms. Keiley was assistant general counsel of Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc., an orthopedic device manufacturer. Prior to working at Zimmer, Ms. Keiley was a trial lawyer and partner with Wildman, Harrold, Allen & Dixon in Chicago, Illinois. Ms. Keiley received her B.S. and B.A. degrees in Psychology and Philosophy, respectively, from Boston College and her J.D. from Loyola University School of Law.

What is Elizabeth M. Keiley's net worth?: The estimated net worth of Elizabeth M. Keiley is at least $58,972.32 as of March 4th, 2019. Ms. Keiley owns 26,928 shares of Entasis Therapeutics stock worth more than $58,972 as of December 17th. This net worth evaluation does not reflect any other assets that Ms. Keiley may own. Learn More about Elizabeth M. Keiley's net worth.
How old is Elizabeth M. Keiley?: Ms. Keiley is currently 56 years old. There are 6 older executives and no younger executives at Entasis Therapeutics. The oldest executive at Entasis Therapeutics is Dr. John Patrick Mueller Ph.D., Chief Devel. Officer, who is 62 years old. Learn More on Elizabeth M. Keiley's age.
How do I contact Elizabeth M. Keiley?: The corporate mailing address for Ms. Keiley and other Entasis Therapeutics executives is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. Entasis Therapeutics can also be reached via phone at (781) 810-0120 and via email at [email protected]. Learn More on Elizabeth M. Keiley's contact information.
Has Elizabeth M. Keiley been buying or selling shares of Entasis Therapeutics?: Elizabeth M. Keiley has not been actively trading shares of Entasis Therapeutics during the last quarter. Most recently, Elizabeth M. Keiley sold 3,759 shares of the business's stock in a transaction on Tuesday, October 19th. The shares were sold at an average price of $3.19, for a transaction totalling $11,991.21. Learn More on Elizabeth M. Keiley's trading history.
Who are Entasis Therapeutics' active insiders?: Entasis Therapeutics' insider roster includes Elizabeth Keiley (General Counsel), and Manoussos Perros (Insider). Learn More on Entasis Therapeutics' active insiders.

Elizabeth M. Keiley Insider Trading History at Entasis Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/19/2021	Sell	3,759	$3.19	$11,991.21

Elizabeth M. Keiley Buying and Selling Activity at Entasis Therapeutics

Entasis Therapeutics Company Overview

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Today's Range

Now: $2.19

$2.19

50 Day Range

MA: $2.19

$2.18

$2.20

2 Week Range

Now: $2.19

$1.40

$3.88

Volume

800 shs

Average Volume

239,104 shs

Market Capitalization

$104.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Uncover the Top Gold Stock of the Bull Market

From Huge Alerts | Ad

Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?

Click here to see how this opportunity could transform your portfolio.